Intech Investment Management LLC Buys New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Intech Investment Management LLC purchased a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 18,014 shares of the biopharmaceutical company’s stock, valued at approximately $84,000.

Several other large investors have also recently added to or reduced their stakes in VNDA. Price T Rowe Associates Inc. MD boosted its position in shares of Vanda Pharmaceuticals by 18.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 2,425 shares during the period. SG Americas Securities LLC purchased a new position in Vanda Pharmaceuticals in the 2nd quarter worth approximately $61,000. Bank of New York Mellon Corp grew its position in Vanda Pharmaceuticals by 8.7% in the second quarter. Bank of New York Mellon Corp now owns 257,995 shares of the biopharmaceutical company’s stock valued at $1,458,000 after acquiring an additional 20,721 shares in the last quarter. Panagora Asset Management Inc. raised its stake in shares of Vanda Pharmaceuticals by 4.3% during the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 2,509 shares during the period. Finally, Monaco Asset Management SAM acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth $1,090,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Stock Up 1.3 %

Shares of VNDA opened at $4.84 on Monday. The firm has a market cap of $282.22 million, a price-to-earnings ratio of -17.29 and a beta of 0.76. The business’s 50 day moving average is $4.84 and its two-hundred day moving average is $5.25. Vanda Pharmaceuticals Inc. has a 52-week low of $3.46 and a 52-week high of $6.75.

Insiders Place Their Bets

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the sale, the director now directly owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. This represents a 10.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 price target for the company. StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Tuesday, December 3rd. They set a “hold” rating for the company.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.